Anadys Pharmaceuticals/Roche
On October 17, 2011, Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) entered into a definitive merger agreement to be acquired by Roche (OTCBB: RHHBY). Under the terms of the merger agreement, Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys at $3.70 per share.
The $3.70 per share cash offer price represents a 256% premium over the closing price of $1.04 on October 14, 2011.
Lazard is acting as financial advisor to Anadys and Cooley LLP is serving as Anadys' legal advisor.
Closing is expected in Q411.
The $3.70 per share cash offer price represents a 256% premium over the closing price of $1.04 on October 14, 2011.
Lazard is acting as financial advisor to Anadys and Cooley LLP is serving as Anadys' legal advisor.
Closing is expected in Q411.
